MaryVan Den Berg-WolfMDFACP, DABMA

PubMed

• 39 citations
  Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as ini...
  Mary van den Berg-Wolf, Katherine Huppler Hullsiek, Grace Peng, Michael J. Kozal, Richard M. Novak
  HIV Clinical Trials. 2008-09-01
• 48 citations
  Ethnicity, race, and gender. Differences in serious adverse events among participants in an antiretroviral initiation trial: results of CPCRA 058 (FIRST Study).
  Ellen Tedaldi, Judith Absalon, Avis J. Thomas, Judith C. Shlay, Mary van den Berg-Wolf
  Journal of Acquired Immune Deficiency Syndromes. 2008-04-01
• 103 citations
  A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in ...
  Rodger D. MacArthur, Richard M. Novak, Grace Peng, Li Chen, Ying Xiang
  Lancet. 2006-12-16

Journal Articles

• Acupuncture is More Than Placebo Treatment  
  van den Berg-Wolf M, Am J Med, 1/1/2014
• CME Article: Electronic Cigarettes: A Perspective for the Primary Care Physician Perspectives  
  Simoncini, GM, Kamal Khan E, van den Berg-Wolf M, Southern Medical Journal, 1/1/2014
• Elevated Testosterone Levels in HIV-Infected Men-Case Report and a Retrospective Chart Review  
  Phongtankeul V, Shrank G, Holtzman C, Campbell E, Gaughan J and van den berg-Wolf M, Journal of the International Association of Providers of AIDS Care, 6/4/2013
• Sadness in the SUN: Using Computerized Screening to Analyze Correlates of Depression and Adherence in HIV-Infected Adults in the United States  
  Tedaldi EM, van den Berg-Wolf M, Richardson J, Patel P, Durham M, Hammer J, Henry K, Metzler S, Önen N, Conley L, Wood K, Brooks JT, Buchacz K, and the SUN Study Inves..., AIDS Patient Care and STDs, 12/1/2012
• Minority HIV Patients' Perceptions of Barriers and Facilitators to Participation in Clinical Research  
  Wolak C, Bass S, Tedaldi E, van den Berg-Wolf M, Rohrer C, Current HIV Research, 6/1/2012
• A 64-year-old HIV-infected man presents for preoperative risk assessment prior to a total hip replacement  
  Simoncini GM, DeFrancesch G, van den Berg-Wolf M, The Consultant, 1/1/2012
• Smoking-Related Health Risks Among Persons With HIV in the Strategies for Management of Antiretroviral Therapy Clinical Trial  
  Lifson AR, Neuhaus J, Arribas JR, van den Berg-Wolf M, Labriola AM, Read T, Am J Public Health, 10/1/2010
• Preoperative cardiac evaluation for noncardiac surgery; a critical review  
  Taqui BS, McNellis K, Coppola K, Shishodia H, Defrancesch G, Berg-Wolf MG vd, Kaplan LI, Moyer DV, J Clin Outcomes Management, 6/1/2009
• Optimizing Management Strategies in Patients with Chronic Hepatitis B Infection-Optimum Dosing Lamivudine Challenged For HIV-1 Infected Patients  
  van den Berg-Wolf M and Tedaldi EM, American Journal of Medicine, 1/1/2009
• Immune Reconstitution Inflammatory Syndrome (IRIS) Manifesting as Anogenital HSV-2 Infection in a HIV-1-Infected Patient After Initiation of Raltegravir  
  Tessing S, Klibanov OM, van den Berg-Wolf M, The Internet Journal of Infectious Diseases, 1/1/2009
• Ezetimibe Combined with Low Dose Statin Effectively Lowers LDL in Protease Inhibitor Treated Patients  
  van den Berg-Wolf M, Klibanov OM, Gaughan JP, Tedaldi EM, MD, AIDS Patient Care and STDs, 1/1/2008
• Virologic, Immunologic, Clinical, Safety, and Resistance Outcomes from a Long-Term Comparison of Efavirenz-Based Versus Nevirapine-Based Antiretroviral Regimens as Ini...  
  van den Berg-Wolf M, Huppler Hulsiek K, Peng G, Kozal MJ, Novak RM Chen L, Crane LR, and MacArthur RD for the CPCRA 058 Study Team, the Terry Beirn Community Programs ..., HIV Clinical Trials, 1/1/2008
• Ethnicity, race and gender: differences in serious adverse events among participants in an antiretroviral initiation trial Results of CPCRA 058 (FIRST)  
  Tedaldi E, Absalon J, Thomas AJ, Shlay JC and van den Berg-Wolf M, JAIDS, 1/1/2008
• IM Board Review Manual on Primary Care Prevention Smoking Cessation  
  Chandrasekaran S and van den Berg-Wolf M, Hospital Physician, 12/1/2007
• The Incidence of HIV Drug Resistance and Its Impact on Progression of HIV Disease Among Antiretroviral-Naïve Participants Started on Three Different Antiretroviral The...  
  Kozal MK, Huppler Hullsiek K, MacArthur RD, van den Berg-Wolf MG, Peng G, Xiang Y, Baxter JD, UY J, Telzak E and Novak RM for the Terry Beirn Community Programs for Cl..., HIV Clinical Trials, 1/1/2007
• A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in ...  
  MacArthur RD, Novak RM, Peng G, Chen L, Xiang Y, Huppler Hullsiek K, Kozal MJ, van den Berg-Wolf M, Henely C, Schmetter B, Dehlinger M for the CPCRA 058 Study Team, The Lancet, 1/1/2006
• Effects of Ezetimibe on Creatinine Phosphokinase and Hepatic Transaminases in an HIV-Positive, Renal Transplant Patient  
  O Klibanov, M van den Berg-Wolf, E Tedaldi, Infectious Disease in Clinical Practice, 1/1/2006
• Prospective Randomized Trial of Educational Materials, Pill Boxes, and Mailings to Improve Adherence with Antiretroviral Therapy in an Inner City HIV Clinic  
  Todd Levin DO, Olga Klibanov PharmD, Peter Axelrod MD, Mary van den Berg-Wolf MD, Gloria Finley CRNP, Anastasia Gray CRNP, Catherine Holdsworth CRNP, Darilyn Moyer MD,..., Journal of Clinical Outcomes Management, 1/1/2006
• Prevalence of Antiretroviral Drug Resistance Mutations in Chronically HIV-Infected, Treatment Naïve Participants in the CPCRA FIRST Study: Implications for Routine Res...  
  RM Novak, L Chen, RD MacArthur, J Baxter, K Huppler-hullsiek, G Peng, Y Xiang, C Henley, B Schmetter, J Uy, M van den Berg-Wolf, M Kozal and the CPCRA 058 Study Team for, Clin Infect Dis, 1/1/2005
• Efficacy and Safety of Abacavir plus Lamivudine versus Didanosine plus Stavudine when Combined with a Protease Inhibitor, a Non-Nucleoside Reverse Transcript Inhibitor...  
  R.D. MacArthur, L Chen, G Peng, R.M. Novak, M van den Berg-Wolf, M Kozal, L Besch, T Yurik, B Schmetter, C Henley, M Dehlinger and the CPCRA 058 Study Team for the Ter..., HIV Clinical Trials, 1/1/2004
• The Rationale and Design of the CPCRA (Terry Beirn Community Programs for Clinical Research on AIDS) 058 FIRST (Flexible Initial Retrovirus Suppressive Therapies) Trial  
  R.D. MacArthur, L. Chen, D.L. Mayers, C. L. Besch, R. Novak, M. van den Berg-Wolf et al, Controlled Clinical Trials, 1/1/2001
• Behandeling van Patienten met AIDS met Zidovudine (Treatment of Patients with AIDS using Zidovudine)  
  L. Buys, R.N.I. Pietersz, M.G. van den Berg-Wolf, H.W. Reesink, J.H. ten Veen, Nederlands Tijdschrift voor Geneeskunde, 1/1/1990
• Recurrent Hemolytic Uremic Syndrome in a Renal Transplant Recipient and Review of the Leiden Experience  
  M.G. van den Berg-Wolf, A.M.M. Kootte, J.J. Weening, L.C. Paul, Transplantation, 1/1/1988
• Complete Remission of an AIDS-related B-cell Lymphoma with One Course of Chemotherapy followed by Azidothymidine Treatment  
  M.G. van den Berg-Wolf, R.N.I. Pietersz, H.W. Reesink, G. Brutel de la Riviere, J.H. ten Veen, AIDS, 1/1/1988
• Join now to see all

Books/Book Chapters

• Women's Health Care: Clinical Vignettes 
  Chapter: Newly Diagnosed HIV Infection. 
  Mary G. Van den Berg-Wolf, MD (Co-author)Editors: Laure Veet.Hanley and Belfus, Inc., Philadelphia, PA2000
• Elseviers Geneesmiddelen Almanak 
  Mary G. Van den Berg-Wolf, MD (Co-author)Amsterdam/Brussels1987

Abstracts/Posters

• Using perceptual mapping methods to understand gender differences in perceived barriers and benefits to HIV clinical research participation: A study with urban minorit...
  Bauerle Bass S, Wolak C, Tedaldi E, van den Berg-Wolf M, Rohrer C, American Public Health Association Annual Meeting, Washington, DC, 10/1/2010
• Failing Therapy with Efavirenz Results in Significantly Fewer Mutations Limiting to Etravirine than Failing Therapy with Nevirapine: On-treatment analyses from the CPC...
  MacArthur RD, Huppler Hulsiek K, Peng G, van den berg-Wolf M, Novak RM, Chen L, and Kozal MJ for the Terry Beirn Community Programs for Clinical Research on AIDS (CPCR..., XVII International HIV Drug Resistance Workshop, Sitges, Spain, 6/1/2008
• Ezetimibe Combined with Low Dose Statins Effectively Lowers LDL in Protease Inhibitor Treated Patients.
  Klibanov OM, Gaughan JP, Tedaldi EM, Lattanzi K, Parekh AN, Gallagher K, van den berg-Wolf M, International AIDS Society Conference, Sydney, Australia, 8/1/2007
• The Effect of Ezetimibe (EZB) on the Steady State Trough Levels of Lopinavir/ritonavir (LPV/r).
  Klibanov OM, Gaughan JP, Tedaldi EM, Lattanzi K, Gallagher K, van den berg-Wolf M, 8th International Workshop on Pharmacology of HIV Therapy, Budapest, 4/1/2007
• Long-Term Clinical and Immunologic Outcomes Are Similar in HIV-Infected Persons Randomized to NNRTI vs. PI vs. NNRTI+PI-based Antiretroviral Regimens as Initial Therap...
  MacArthur RD, Novak RM, Peng G, Chen L, Xiang Y, Kozal MJ, van den Berg-Wolf M, Henely C, Huppler-Hullsiek K, Schmetter B, Dehlinger M, International AIDS Society Conference, Toronto, Canada, 8/1/2006
• Efficacy and Safety of Nevirapine versus Efavirenz When Combined in ART Regimens in HIV Infected antiretroviral-Naïve Persons (The NNRTI Substudy of FIRST-CPCRA 058).
  van den Berg-Wolf M, Peng G, Xiang Y, Huppler Hullsiek K, Chen L, MacArthur RD, Novak RM, Kozal M, Schmetter B, Henely C, Dehlinger M, International AIDS Society Conference, Toronto, Canada, 8/1/2006
• Initial Virologic Failure with HIV Drug Resistance and Impact of Resistance on Disease Progression and Death for Patients Beginning PI, NNRTI or PI+NNRTI Based Strateg...
  Kozal MJ, Huppler Hullsiek K, MacArthur RD, Peng G, Xiang Y, Baxter JD, Van den Berg-Wolf M, XV International HIV Drug Resistance Workshop, Sitges, Spain, 6/1/2006
• Prevalence of Resistance Mutations in a Cohort of Treatment-naïve People with Chronic HIV infection: CPCRA 058.
  RM Novak, L Chen, RD MacArthur, J Baxter, K Huppler Hullsiek,, G Peng, Y Xiang, C Henley, B Schmetter, J Uy, M van den Berg-Wolf, M Kozal and the CPCRA 058 Study Team, International AIDS Society Conference, Thailand, 7/1/2004
• Efficacy and Safety of ABC+3TC versus ddI+d4T when Combined with a PI, NNRTI or Both in AR-Naive Persons on Their First HAART Regimen: The NRTI Substudy of the CPCRA 0...
  RD MacArthur, L Chen, G Peng, RM Novak, M van den Berg-Wolf, M Kozal, L Besch, T Yurik, B Schmetter, C Henley, M Dehlinger for the Terry Beirn Community Programs for C..., International AIDS Society Conference, Paris, 7/1/2003
• A Description of an Interactive HIV/AIDS teaching Tool Designed For Low Literacy Patients.
  M.G. van den Berg-Wolf, S. Lassiter, S.B.C. Hammerman, A. Chammaro, E.M. Tedaldi, Journal of General Internal Medicine, 1/1/2000
• HIV Care Standards Equivalent Regardless of Type of Outpatient Practitioner.
  M.G. van den Berg-Wolf, et al, XIth International AIDS Society Conference, Vancouver, 7/1/1996
• Medical Residents Provide Quality Care to HIV-Infected Outpatients.
  M.G. van den Berg-Wolf, et al, Journal of General Internal Medicine, 1/1/1996
• Surveillance of HIV Antibody Testing in an Urban Academic Center.
  E. Tedaldi, N. Miller, J. Tseng, M.G. van den Berg-Wolf, D. Moyer, Journal of General Internal Medicine, 1/1/1996
• Granulocyte Macrophage Colony Stimulating Factor (GMC-SF) Increased the Number of Neutrophils and Eosinophils in Zidovudine Associated Leukopenia.
  M.G. van den Berg-Wolf, et al, VII International AIDS Society Conference, Florence, 7/1/1991
• Megaloblastic Changes in the Bone Marrrow of AZT Treated AIDS as a Prognostic Marker for Need of Blood Transfusion.
  M.G. van den Berg-Wolf, et al, IV-International AIDS Society Conference, Stockholm, 6/1/1988
• Recurrent Hemolytic Uremic Syndrome in a Renal Transplant Recipient and Review of the Leiden Experience.
  M.G. van den Berg-Wolf, et al, Xth International Congress of Nephrology, London, 7/1/1987
• Join now to see all